ArticleFrontiers in global women's health2025
Global burden and trends of pelvic inflammatory disease associated with sexually transmitted infection excluding HIV from 1990 to 2021.
Article in Frontiers in global women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Global and Regional Impact of Pelvic Inflammatory Disease in Females Across All Age Groups (1990-2021) with Projections to 2046: Findings from the 2021 Global Burden of Disease Study.International journal of women's health · 2026Article
- Inducing factors and complication risks of pelvic inflammatory disease: a review.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pelvic inflammatory disease (PID) is mainly induced by the sexually transmitted infection (STI). However, the global burden and trends of STI excluding human immunodeficiency virus (HIV)-associated PID (non-HIV PID) has not been specifically assessed. Methods: The prevalence and years lived with disability (YLDs) were collected from the Global Burden of Disease (GBD) 2021 database. The disease burden was evaluated with the case numbers, age-standardized rates (ASR) and estimated annual percentage changes (EAPC). According to the SocioDemographic Index (SDI), frontier and health inequality analysis were conducted. Autoregressive Integrated Moving Average (ARIMA) model was applied to predict the future trends of Non-HIV PID. Results: The age-standardized prevalence rates (ASPR) and YLDs of non-HIV PID was 27.02/100,000 and 3.68/100,000 in 2021 globally. Except for the decline of gonococcal-associated PID, the EAPC of chlamydial and other non-HIV PID were stable. The countries with fastest-growing prevalence were Brazil (4.19 [2.92, 5.47]), Spain (3.98 [3.19, 4.77]), Greece (3.05 [2.55, 3.55]), Portugal (2.76 [2.22, 3.29]), which suggested the increased burden of non-HIV PID in these years. Moreover, the non-HIV PID was mainly concentrated in 30-34 years, which was most common in the low and low-middle SDI. Additionally, prevention of non-HIV PID should also be concerned in the high SDI regions, especially for United Kingdom, Canada, Japan, and Singapore, which would also increase in the next 30 years. Conclusion: The burden and prevention of non-HIV PID were still arduous and required a long-term effort, especially for the 30-34 years, which need more attentions even for the developed countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.